TD Cowen analyst Ken Cacciatore raised the firm’s price target on Biohaven (BHVN) to $75 from $55 and keeps a Buy rating on the shares. The firm said they expect Phase III data for T-alfa in SMA where the risk/reward is favorable. And by year end they expect the SAD/MAD/subQ IgG degrader data update for BHV-1300 and IND submissions for 3 additional MoDE degrader platform candidates.
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHVN:
- Biohaven reports Q3 adjusted EPS ($1.74), consensus ($1.70)
- Biohaven options imply 19.6% move in share price post-earnings
- Biohaven price target raised to $65 from $63 at BofA
- RBC says Scholar Rock ‘win’ in SMA has favorable Biohaven implications
- Biohaven price target raised to $68 from $55 at JPMorgan